Insider Buy: Precigen
4:08PM ET 1/31/2023 MT NewswiresRandal J Kirk, 10% Owner, Director, on January 27, 2023, executed a purchase for 11,428,571 shares in Precigen (PGEN) for $19,999,999. Following the Form 4...
Quotes Snapshot > PGEN
Precigen Inc PGEN:NASDAQ
Last Price$1.81NASDAQ Previous Close - Last Trade as of 4:00PM ET 2/08/23
Today's Change-0.06(3.21%)
Bid (Size)$1.79 (2)
Ask (Size)$1.88 (10)
Day Low / High$1.78 - 1.89
Volume1.9 M
Read more news Recent News
--Cantor Fitzgerald Adjusts Price Target on Precigen to $10 From $7, Maintains Overweight Rating
10:34AM ET 1/30/2023 MT Newswires(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Precigen Closes $75 Million Common Stock Offering
4:27AM ET 1/30/2023 MT NewswiresPrecigen (PGEN) said Friday it has closed its public offering of common stock, raising about $75 million in gross proceeds. The company said it has sold...
Sector Update: Health Care Stocks Largely Sit Out Late Market Rebound
4:09PM ET 1/25/2023 MT NewswiresHealth care stocks were ending little changed this afternoon, with the NYSE Health Care Index climbing 0.1% and the Health Care Select Sector SPDR Fund...
View all Commentary and Analysis
Precigen: Will Financing Issues Forever Cloud The Promise?
7:34AM ET 1/31/2023 Seeking AlphaMiller Opportunity Equity 3Q22 Quarterly Investment Review
9:45PM ET 10/26/2022 Seeking AlphaCircling Back On Precigen
5:24PM ET 8/23/2022 Seeking AlphaPrecigen, Inc. (PGEN) CEO Helen Sabzevari on Q2 2022 Results - Earnings Call Transcript
8:21PM ET 8/08/2022 Seeking AlphaCompany Profile
Business DescriptionPrecigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD. View company web site for more details
| Address | 20358 Seneca Meadows Parkway Germantown, Maryland 20876 |
| Phone | +1.301.556.9900 |
| Number of Employees | 882 |
| Recent SEC Filing | 01/31/2023 4 |
| President, Chief Executive Officer & Director | Helen Sabzevari |
| Chief Operating Officer | Rutul R. Shah |
| Chief Financial Officer | Harry Thomasian |
| Chief Science Officer | Thomas David Reed |
Company Highlights
| Price Open | $1.89 |
| Previous Close | $1.87 |
| 52 Week Range | $1.12 - 2.90 |
| Market Capitalization | $454.3 M |
| Shares Outstanding | 251.0 M |
| Sector | Health Technology |
| Industry | Biotechnology | Next Earnings Announcement | 03/07/2023 |
Options Summary
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
View all fundamentalsFundamentals
| Price / Earnings | 15.25 |
| Earnings per Share | -$0.34 |
| Beta vs. S&P 500 | N/A |
| Revenue | $160.6 M |
| Net Profit Margin | -102.78% |
| Return on Equity | -82.23% |
Analyst Ratings as of 11/17/2022
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |